{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-015908","form_type":"8-K","ticker":null,"cik":"0001840904","company_name":"ATAI Life Sciences N.V.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.915481+00:00","generated_at":"2026-06-04T06:32:38.205973+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Atai Life Sciences reports Q4 2023 net loss $18.3M, cash $154.2M; BPL-003 Phase 2a shows 45% remission at 3 months","bullets":["Net loss for Q4 2023 was $18.3M vs $45.0M in Q4 2022; full-year net loss $40.2M vs $152.4M.","Cash and short-term investments $154.2M as of Dec 31, 2023, down from $273.1M a year ago.","R&D expenses decreased to $62.2M for FY 2023 from $74.3M; G&A expenses decreased to $63.6M from $70.4M.","Strategic investment in Beckley Psytech (Jan 2024) added BPL-003 and ELE-101; Phase 2b BPL-003 results expected 2H 2024.","VLS-01 Phase 1b dosing initiated; COMP360 Phase 3 top-line data expected Q4 2024 and mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-015908","json":"https://secwatch.observer/filing/0001140361-24-015908.json","markdown":"https://secwatch.observer/filing/0001140361-24-015908.md","text":"https://secwatch.observer/filing/0001140361-24-015908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840904/000114036124015908/0001140361-24-015908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840904/000114036124015908/ef20025361_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:32:38.205973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88e857755b5ffa81159c941b0da4cae11b8cc32d","claim":"ATAI Life Sciences N.V. reported financial results for Q4 and FY 2023.","evidence_excerpt":"atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced fourth quarter and full year 2023 financial results and provided corporate and clinical highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036124015908/0001140361-24-015908-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q4 and FY 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}